CLAIMS

1. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising an amino acid substitution of D265G and one or more amino acid substitutions at positions 234, 235, 237, 329, 330, or 331, wherein the residues are numbered according to the EU index.

2. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 234V, 235E, and D265G, wherein the residues are numbered according to the EU index.

3. The isolated polypeptide of claim 2, wherein the Fc variant is IgG4 Fc region and comprises amino acid substitutions of S228P, F234V, L235E, and D265G.

4. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 234F, 235E, and D265G, wherein the residues are numbered according to the EU index.

5. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 234V, 235A, G237A, and D265G, wherein the residues are numbered according to the EU index.

6. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 235E and D265G, wherein the residues are numbered according to the EU index.

7. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 235E, G237A, and D265G, wherein the residues are numbered according to the EU index.

8. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 235E, G237A, and P329G, wherein the residues are numbered according to the EU index.

9. The isolated polypeptide of claim 8, wherein the Fc variant comprises amino acid substitutions of S228P, L235E, G237A, and P329G.

10. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 235E, G237A, and L328R, wherein the residues are numbered according to the EU index.

11. The isolated polypeptide of claim 10, wherein the Fc variant comprises amino acid substitutions of S228P, L235E, G237A, and L328R.

12. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of D265G, A330S, and P331S, wherein the residues are numbered according to the EU index.

13. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 235E, D265G, A330S, and P331S, wherein the residues are numbered according to the EU index.

14. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising amino acid substitutions of 235E, D265G, and P329G, wherein the residues are numbered according to the EU index.

15. The isolated polypeptide of any one of the preceding claims, wherein the Fc variant is an IgG1, an IgG2, or an IgG4 Fc region.

16. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc region, said Fc variant comprising an amino acid substitution of D265G, wherein the residues are numbered according to the EU index, and wherein the Fc variant has a reduced affinity for a human FcγR as compared to the wild-type IgG Fc region.

17. An antibody comprising an isolated polypeptide of any one of claims 1-16.

18. A nucleic acid encoding an isolated polypeptide of any one of the preceding claims.

19. A cell comprising nucleic acid of claim 18.

20. A method of making an isolated polypeptide of any one of claims 1-16, said method comprising; culturing a host cell comprising a nucleic acid encoding the antibody or antigen binding fragment thereof, and culturing the cell under conditions that allow production of the isolated polypeptide.

21. Use of an isolated polypeptide of any one of claims 1-16, or an antibody of claim 17, in the manufacture of a medicament for treating a disease or disorder.

22. An isolated polypeptide of any one of claims 1-16, or an antibody of claim 17, for use in the treatment of a disease or disorder.